Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 10/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.59 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.58 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.58 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.58 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.58 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.58 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.58 |
| ▸ | GSAP | A4D1B5 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5016379 | 0.94 | CCKBR (0.78) | CCKBRKCNH2SCN9APSEN1PSEN2 | |
| SCHEMBL5016293 | 0.92 | CCKBR (0.69) | CCKBRKCNH2SCN9APSEN1PSEN2 | |
| SCHEMBL5018003 | 0.92 | CCKBR (0.69) | CCKBRKCNH2SCN9A | |
| SCHEMBL5017932 | 0.90 | CCKBR (0.67) | CCKBRKCNH2SCN9APSEN1PSEN2 | |
| SCHEMBL5023270 | 0.90 | CCKBR (0.67) | CCKBRKCNH2SCN9APSEN1PSEN2 | |
| SCHEMBL5026491 | 0.88 | CCKBR (0.67) | CCKBRKCNH2PSEN1PSEN2APH1B | |
| SCHEMBL5016371 | 0.88 | PSEN1 (0.73) | CCKBRKCNH2PSEN1PSEN2APH1B | |
| SCHEMBL5017900 | 0.86 | CCKBR (0.62) | CCKBRKCNH2SCN9APSEN1PSEN2 | |
| SCHEMBL5022594 | 0.86 | PSEN1 (0.66) | CCKBRKCNH2SCN9APSEN1PSEN2 | |
| SCHEMBL5016321 | 0.86 | CCKBR (0.66) | CCKBRKCNH2SCN9APSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1592684-B1 | MALONAMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-07-30 | — | — | EP | disclosed |
| US-7375099-B2 | secretase inhibitors; therapy for Alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-20040220222-A1 | Malonamide derivatives | F. HOFFMAN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220222-A1 | Malonamide derivatives | BACE1, BACE2, APP | CCKBR 916/4885KCNH2 1943/4885SCN9A 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.